Taysha Gene Therapies Q3 2026 Earnings Date & Estimates

Taysha Gene Therapies (NASDAQ:TSHA) (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. The company uses adeno-associated virus-based delivery technologies and other genetic medicine approaches to target conditions with limited or no approved treatment options.

Taysha’s research and development programs have included TSHA-102, an investigational gene therapy being developed for Rett syndrome, as well as programs for other rare neurological disorders. Its candidates are designed to deliver therapeutic genetic material to affected cells, with the goal of addressing the underlying causes of disease rather than treating symptoms alone. The company’s therapies remain investigational and are subject to clinical and regulatory review.

Founded in 2019 and headquartered in Dallas, Texas, Taysha was established in collaboration with researchers at UT Southwestern Medical Center. The company’s operations are primarily focused on advancing its pipeline through clinical development and regulatory processes in the United States, with potential global applications for rare neurological diseases. R.A. Session serves as president and chief executive officer.